{"id":701821,"date":"2022-10-27T08:19:46","date_gmt":"2022-10-27T12:19:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/"},"modified":"2022-10-27T08:19:46","modified_gmt":"2022-10-27T12:19:46","slug":"jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/","title":{"rendered":"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">CAMBRIDGE, Mass., Oct.  27, 2022  (GLOBE NEWSWIRE) &#8212; Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics&#8217; management team will host a webcast and live conference call at 8:00 a.m. ET.<\/p>\n<p align=\"justify\">\n        <strong>Conference Call and Webcast<\/strong><br \/>\n        <br \/>To access the conference call, please register <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-zye8o_cl1GZz-p5fWCQ4hS881kdmnPqJ-BhFFhfVM6EuqL0hZmDKyuIlNTgik1B6YTIaj5t7JzlL_EvFpn8TvHHP5Djrt3B3GCzfWEo8sH0c72K06iJ8M1KukaSbdUDPAqxqG60WnRx6HKmg-N8Yw==\" rel=\"nofollow noopener\" target=\"_blank\"><u>here<\/u><\/a> and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under &#8220;Events &amp; Presentations&#8221; in the Investors and Media section of the company&#8217;s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mXamxTopgWjM-GvUyHAMUWmI1gJA5PJGDgCQ_GwYwKm26gK0yNR_GYB1biAZFqWQ7hdM_MZkXj_3lBnkw-Emwg==\" rel=\"nofollow noopener\" target=\"_blank\">www.jouncetx.com<\/a>. The webcast will be archived and made available for replay on the company\u2019s website approximately two hours after the call and will be available for 30 days thereafter.<\/p>\n<p align=\"justify\">\n        <strong>About Jounce Therapeutics:<br \/><\/strong>Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and may provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce\u2019s highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. JTX-8064 is currently being investigated alone and in combination with pimivalimab (formerly JTX-4014), Jounce\u2019s internal PD-1 inhibitor, in one monotherapy and seven indication-specific combination therapy cohorts in the Phase 1\/2 INNATE trial and is currently enrolling patients with advanced solid tumors in the Phase 2 portion of the study. Jounce\u2019s most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. Pimivalimab is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce\u2019s broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to GS-1811 (formerly JTX-1811), a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc. For more information, please visit www.jouncetx.com.<\/p>\n<p>\n        <strong>Investor and Media Contacts:<\/strong><br \/>\n        <br \/>Eric Laub<br \/>Jounce Therapeutics, Inc.<br \/>+1-857-259-3853<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iQIYM-XoHIuFESWs4yVLcB2DqiS2XaCIS1QfbOyCkBvxwvwKscwZ4pao8bJqdXRAygKil8Nf-NAcaXcjtqrDL3dBIp7UQikwZLQIQg0tRLE=\" rel=\"nofollow noopener\" target=\"_blank\">elaub@jouncetx.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODhiZGM5MjktN2YwYi00MjA0LTk3NmEtYmYwZjMyNTUzYmI5LTEwMzc3MTE=\/tiny\/Jounce-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics&#8217; management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under &#8220;Events &amp; Presentations&#8221; in the Investors and Media section of the company&#8217;s website at www.jouncetx.com. The webcast will be &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-701821","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics&#8217; management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under &#8220;Events &amp; Presentations&#8221; in the Investors and Media section of the company&#8217;s website at www.jouncetx.com. The webcast will be &hellip; Continue reading &quot;Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-27T12:19:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022\",\"datePublished\":\"2022-10-27T12:19:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/\"},\"wordCount\":395,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/\",\"name\":\"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=\",\"datePublished\":\"2022-10-27T12:19:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/","og_locale":"en_US","og_type":"article","og_title":"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022 - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) &#8212; Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, today announced that it will report third quarter 2022 financial results and provide a corporate update on Thursday, November 10, 2022. Jounce Therapeutics&#8217; management team will host a webcast and live conference call at 8:00 a.m. ET. Conference Call and Webcast To access the conference call, please register here and please be advised to do so at least 10 minutes prior to joining the call. The live webcast can be accessed under &#8220;Events &amp; Presentations&#8221; in the Investors and Media section of the company&#8217;s website at www.jouncetx.com. The webcast will be &hellip; Continue reading \"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/","og_site_name":"Market Newsdesk","article_published_time":"2022-10-27T12:19:46+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022","datePublished":"2022-10-27T12:19:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/"},"wordCount":395,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/","name":"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=","datePublished":"2022-10-27T12:19:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODY4MzIxNCM1MjI2ODQyIzIwMjYxMzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/jounce-therapeutics-to-announce-third-quarter-2022-financial-results-and-host-conference-call-on-thursday-november-10-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701821","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=701821"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/701821\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=701821"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=701821"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=701821"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}